Dow Jones Top Company Headlines at 5 PM ET: Apple Unveiled the New Siri AI. Here Are the Key Takeaways. | Amazon ...

Dow Jones
Jun 09

Apple Unveiled the New Siri AI. Here Are the Key Takeaways.

Apple showed off a new version of its Siri chatbot, technology developed with Google that the iPhone maker hopes will help power a comeback in AI.

----

Amazon Enters Agreement With Corning for Optical Fiber for Data Centers

Amazon.com said it entered a multibillion-dollar agreement with Corning to get optical fiber, cable and connectivity solutions to support its growing data center footprint.

----

Campbell's Sales Fall on Continued Weak Demand for Snacks

Campbell's sales fell in the fiscal third quarter, driven in part by further declines in its snacks business, but said its profit rose.

----

Vail Resorts Cuts Outlook Again as Weather Weighs on Visits

The ski-resort operator said weather conditions remained extremely unfavorable during the recent quarter, weighing on visits and revenue, particularly at Vail's resorts in the Rockies.

----

Nvidia Strikes Deals With Korean Tech Titans for AI Infrastructure Buildout

Nvidia is teaming up with leading South Korean technology companies to build large-scale artificial-intelligence infrastructure in Asia, seeking to solidify its data-center footprint and expand its AI ecosystem.

----

Intesa Bids $35 Billion for Monte dei Paschi

The approaches pit Intesa and BPM against each other for control of their domestic rival, continuing a wave of dealmaking activity in Italy's banking industry.

----

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.

----

Honeywell Backs Full-Year Guidance

Honeywell backed its full-year guidance as it looks to close a spinoff of its aerospace division.

----

Ingredion to Take Over Tate & Lyle in $3.6 Billion Deal

Ingredion offered the equivalent of $7.94 for each Tate & Lyle share, a 59% premium to the last closing price before takeover talks were disclosed last month.

----

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.

----

GoHealth Files for Bankruptcy, Handing Control to Lenders

The insurance brokerage, once valued at $6.6 billion, entered chapter 11 with nearly $1 billion in debt and a plan that leaves operations intact.

----

Wix.com Slashes 20% of Staff, Lowers Outlook as Restructuring Continues

The website-building and web-services platform said that it is scaling back parts of its business as part of a broader organizational realignment, moves that are expected to weigh on bookings and revenue growth in 2026.

----

FuelCell Earnings: Wider Loss, Higher Stock

FuelCell Energy stock has more than doubled in 2026 as the data-center buildout fuels demand for the company's fuel cell power plants.

----

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.

----

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks.

----

Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion

The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.

 

(END) Dow Jones Newswires

June 08, 2026 17:00 ET (21:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10